1. Baqsimi is a nasal powder for severe hypoglycemia, which occurs when a patient’s blood sugar falls to a dangerously low level. It usually happens in people who have diabetes. It is the first emergency treatment that can be administered without an injection.
2. Hadlima is a biosimilar to AbbVie’s blockbuster rheumatoid arthritis treatment Humira. It won’t be available in the U.S. until June 2023.
3. Ruxience is a biosimilar to Rituxan, a treatment for Non-Hodgkin lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis and microscopic polyangiitis.
4. The FDA has approved several new generics of Lyrica, a brand-name drug manufactured by Pfizer to treat fibromyalgia, nerve pain and partial onset seizures in patients 17 years of age and older. They are the first FDA-approved generics for the drug, pregabalin.
More articles on pharmacy:
9 recent drug, device recalls
Owens Healthcare to sell 12 retail pharmacies to CVS
The pharmacies that received the most opioids in every state
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
